• Explore /
  • Poster
  • / A randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator's choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy.

A randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator's choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy.

Abstract Poster

Authors

null

Omer Hassan Jamy

University of Alabama at Birmingham, Birmingham, AL

Omer Hassan Jamy , Sharif S. Khan , Panagiotis Tsirigotis , Benjamin Kent Tomlinson , Mathilde Hunault-Berger , Uwe Platzbecker , Ioanna Sakellari , Ana Vidovic , Pau Montesinos , Teresa Bernal del Castillo , Daniel Egan , Hana Safah , Gary J. Schiller , Mathias Haenel , Agata Obara , Tsung-Chih Chen , Marcello Rotta , Stavroula Giannouli , Aleksandar Savic , Dragan Cicic

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT04229979

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS7074)

DOI

10.1200/JCO.2023.41.16_suppl.TPS7074

Abstract #

TPS7074

Poster Bd #

203b

Abstract Disclosures

Similar Posters

First Author: Geoffrey L. Uy

First Author: Joseph J. Sacco

First Author: Maria Amaya

First Author: Andrea Cercek